

# A Systematic Review on Malaria and Tuberculosis (TB) Vaccine Challenges in Sub-Saharan African Clinical Trials

Maonezi Abas Hamisi<sup>1\*</sup>, Nur Ain Mohd Asri<sup>2</sup>, Aini Syahida Mat Yassim<sup>3</sup>, Rapeah Suppian<sup>4</sup>

<sup>1</sup>School of Science and Technical Education (CoSTE), Mbeya University of Science and Technology, Tanzania;

<sup>2,3,4</sup>School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.

\*Corresponding author: Maonezi Abas Hamisi, School of Science and Technical Education (CoSTE), Mbeya University of Science and Technology, Tanzania; [hamisi2012maonezi@gmail.com](mailto:hamisi2012maonezi@gmail.com), +255763457088, P.O. Box 131 Mbeya, Tanzania

---

## Abstract

**Objective:** For more than a century, developing novel and effective vaccines against malaria and tuberculosis (TB) infections has been a challenge. This review sought to investigate the reasons for the slow progress of malaria and TB vaccine candidates in sub-Saharan African clinical trials.

**Methods:** The systematic review protocol was registered on PROSPERO on July 26, 2023 (CRD42023445166). The research articles related to the immunogenicity, efficacy, or safety of malaria or TB vaccines that were published between January 1, 2012, and August 31, 2023, were searched on three databases: Web of Science (WoS), PubMed, and ClinicalTrials.gov.

**Results:** A total of 2342 articles were obtained, 50 of which met the inclusion criteria. 28 (56%) articles reported on malaria vaccine attributes, while 22 (44%) articles reported on TB vaccines. In both cases, the major challenges in sub-Saharan African clinical trials were immunogenicity and efficacy, rather than safety.

**Conclusion:** Factors such as population characteristics, pathogen genetic diversity, vaccine nature, strategy, and formulation were associated with slow progress of the malaria and TB vaccine candidates in sub-Saharan African clinical trials.

## Author summary

Vaccines are one of the most powerful control strategies for both infectious and non-infectious diseases. The lack of durable vaccines and the development of antimicrobial resistance have made malaria and

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 TB threats to human lives, specifically in sub-Saharan Africa. The search for novel, reliable, and durable  
31 vaccines against these infections has been underway for more than a decade. Despite this, none have  
32 resulted in vaccines with all three preferred critical attributes: immunogenicity, efficacy, and safety. This  
33 indicates that there are hindering challenges that have been neglected in the development pipeline. This  
34 review focused on understanding these challenges in sub-Saharan African clinical trials. The results of  
35 the study are crucial for the identification of areas for improvement in vaccine design, evaluation, and  
36 implementation strategies, hence driving advancements in NTD vaccine research and development.

37

38 **Keywords**

39 *Malaria vaccines; Tuberculosis vaccines; Sub-Saharan Africa; Clinical trials; Systematic review*

## 40 1. Introduction

41 Malaria and Tuberculosis (TB) are among the top ten causes of death in low- and middle-income countries,  
42 the majority of which are sub-Saharan countries (1). Malaria is a plasmodium-borne infection that is  
43 spread by female Anopheles mosquitoes (2). *Plasmodium falciparum* species are the dominant  
44 cause of human malaria (3). In 2021, 619,000 deaths were caused by malaria worldwide, 95% of  
45 which occurred in sub-Saharan Africa (4). The favourable environment for *P. falciparum* species  
46 (5) and healthcare systems contribute to this prevalence (6). In contrast, human TB is an airborne  
47 disease caused by *Mycobacterium tuberculosis* (Mtb). TB spreads through respiratory system encounters  
48 active Mtb-containing air droplets (7). TB infections were the leading cause of human deaths prior to  
49 COVID-19 (7). Human TB causes 10.6 million cases and 1.6 deaths, 90% of which occurred in  
50 sub-Saharan Africa (7).

51 Currently, chemical drugs, as well as vaccines, are used for the control of malaria (8) and TB (7).  
52 However, the development of resistant strains has made drug use inefficient and costly. Vaccines  
53 are the most effective options for these diseases, and they can help to prevent the spread of  
54 resistance. Despite not being fully certified, the malaria RTS, S/AS01, was recommended for the  
55 pilot vaccination of 5- to 17-month-old children living in high-endemic areas(9). Unlike malaria,  
56 BCG is the only certified TB vaccine. Both RTS, S/AS01 (10), and BCG (11) share similar  
57 limitations: they provide protection but limited to young age groups. Different groups of malaria  
58 vaccine candidates have been tested in sub-Saharan African clinical trials. Some of these include  
59 subunit vaccines (12,13), (14), (15,16), viral-like particle vaccines (17–20), and whole attenuated  
60 vaccines (21–23). Like malaria vaccine candidates, TB vaccine candidates include subunit vaccines  
61 (24–27), (28–30), (31–34), inactivated vaccines (35), and whole attenuated vaccines (11,36,37).  
62 Nevertheless, the progress of malaria and TB vaccine development in sub-Saharan Africa has been  
63 arduous and frequently regarded as sluggish. The aim of this study was to elucidate the barriers  
64 that hinder the rapid advancement of efficacious malaria and TB vaccines, with a specific emphasis

65 on immunogenicity, effectiveness, and safety in sub-Saharan Africa.

## 66 **2. Methodology**

67 The review protocol was registered on PROSPERO (CRD42023445166). In brief, this review  
68 followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)  
69 guidelines (38). The keywords and review questions were formulated based on PICO: Sub-Saharan  
70 Africans (population), malaria and TB vaccine candidates (intervention), non-vaccinated, placebo, or  
71 any control setting (control), immunogenicity, efficacy, and safety (outcomes). The review question  
72 was “What are the challenges that hinder the rapid development of malaria and TB vaccines in sub-  
73 Saharan African clinical trials?”.

### 74 **2.1 Article identification**

75 The review began with the identification of keywords and their respective synonyms by the first and  
76 second authors (HM and NA, respectively). The keywords and synonyms used to formulate the search  
77 strategy were based on the PICO formulation, which includes Sub-Saharan Africans (population),  
78 malaria and TB vaccine candidates (intervention), non-vaccinated, placebo, or any control setting  
79 (control), immunogenicity, efficacy, and safety (outcomes) as summarized in **Table 1**. The search was  
80 performed between the 1st of August 2023 and the 31st of August 2023 on three databases, Web of  
81 Science, PubMed, and ClinicalTrials.gov, with some refinement to meet the inclusion criteria.

### 82 **2.2 Article screening and eligibility**

83 Two authors, HM, and NA screened the articles obtained independently. Malaria or TB vaccine  
84 candidate studies that reported immunogenicity, efficacy, safety, or a combination, involved a sub-  
85 Saharan population, were randomised clinical trials, published in English between January 1, 2012,  
86 and August 31, 2023, were included. Studies not meeting these criteria were excluded. The  
87 discrepancies occurred were resolved by involving the third and fourth authors (AS and RS). The  
88 duplicate and irrelevant articles were removed using Mendeley software (2.107.0, 2023).

89

90

**Table 1:** The search strategy applied in this study.

Databases	Filter	String/Option
<b>Web of Sciences</b>	Only English, Article type, Sub-Saharan Countries by excluding Libya, Egypt, Algeria, Morocco and Tunisia	TS=((("Tuberculosis*" OR "Malaria*" OR "Vaccine" OR "Vaccine candidate") AND ("immunogenicity" OR "safety" OR "efficacy" OR "protect" OR "immune respons*" OR "CD4+" OR "CD8+" OR "antibody respons*")) AND ("Africa" OR "Sub Sahara") NOT ("typhoid" OR "SARS" OR "Covid-19" OR "rotavirus" OR "influenza" OR "ebola" OR "drug" OR "yellow fever"))
<b>PubMed</b>	Full text, Randomized Controlled Trial, Humans, English	((("Malaria") OR ("Tuberculosis")) AND ("vaccin*")) OR ("vaccine candidat*") AND ("immunogenicity")) OR ("safety") OR ("efficacy")) OR ("protect")) OR ("immune respons*")) OR ("CD4+ ") OR ("CD8+")) OR ("antibody respons*")) AND ("Africa")) OR ("Sub Sahara")) NOT ("typhoid")) NOT ("SARS")) NOT ("Covid-19")) NOT ("rotavirus")) NOT ("influenza")) NOT ("ebola")) NOT ("drug")) NOT ("yellow fever"))).
<b>ClinicalTrials.gov</b>	N/A	ClinicalTrials.gov: Immunogenicity OR safety OR efficacy OR CD4+ OR CD8+ OR protection OR immune response OR Africa OR Sub Sahara   Completed Studies   Studies With Results   malaria OR tuberculosis   vaccine OR vaccine candidate   Studies that accept healthy volunteers   Start date from 01/01/2012 to 08/31/2023

91

\*N/A: Not Available

92

93

94

### 2.3 Assessment of study quality

95

The risk of bias in the eligible studies was analysed by the first author (HM) using the Cochrane risk of bias tool (RoB 2)(38). The other three co-authors confirmed the findings (NA, AS, and RS). Each randomised controlled trial was rated as “high,” “low,” or “some concerns” for bias in five domains: randomization process, deviation from intervention, missing outcome data, measurement of outcomes, and selection of reported outcomes.

96

97

98

99

100

### 2.4 Data extraction and synthesis

101

Data were extracted and compiled from all eligible articles on the standard data collection table. The first author's surname, publication year, population, region (country), clinical trial phase, intervention, control, and number of doses were retrieved for the articles. We then performed a narrative synthesis of the literature using our outcome keywords immunogenicity, efficacy, and safety.

102

103


104

105

### 106 3. Results

#### 107 3.1 Study selection

108 The search yielded 2342 publications. 1791 (76.5%) articles were from Web of Sciences, 497 (21.2%)  
109 from PubMed, and 54 (2.3%) from ClinicalTrials.gov. The ClinicalTrials.gov database contained 54  
110 articles from 11 studies (55%) of 20 search projects. To minimise bias, nine (45%) studies had no  
111 publications and were excluded from this review. The 2342 published studies were reduced to 92  
112 (3.9%) duplicates and 2179 (93%) irrelevant. 17 (23.9%) studies were removed after screening titles  
113 and abstracts of 71 (3.0%). After full-text screening, 4 (7.4%) of 54 (76.1%) studies were removed.  
114 Fifty studies were eligible for review; 28 (56%) were malaria vaccines and 22 (44%) were TB  
115 vaccines. The flowchart of this study was summarized in **Figure 1** and **Table 2** highlighted all eligible  
116 studies' characteristics.



117

118

Figure 1. PRISMA flowchart of this study.

**Table 2.** Characteristics of all eligible studies in this review.

Author	Year	Country	Vaccine	Control	Phase	No of doses	Participants	References
<b>Tuberculosis (TB)</b>								
<b>Churchyard et al.,</b>	2015	SouthAfrica	AERAS-402/A D35. TB-S	Placebo	II	2	Adults	(28)
<b>Ndiaye et al.,</b>	2015	South Africa & Senegal	MVA85A	Placebo	II	2	Adults	(24)
<b>Meeren et al.,</b>	2018	Zambia, Kenya, South Africa	M72/AS10E	Placebo	II	2	Adults	(33)
<b>Tait et al.,</b>	2019	Kenya, South Africa, & Zambia	M72/AS01E	Placebo	II	2	Adults	(39)
<b>Tameris et al.,</b>	2019	SouthAfrica	MTBAV	BCG	I & II	3	Infants and adults	(11)
<b>Walsh et al.,</b>	2016	Kenya	AERAS-402	Placebo	I	2	Adults	(30)
<b>Tchakoute et al.,</b>	2014	South Africa	BCG	BCG	II	1	Infants	(40)
<b>Tameris et al.,</b>	2015	SouthAfrica	AERAS-402	Placebo	II	3	Infants	(41)

<b>Penn-Nicholson et al.,</b>	2018	SouthAfrica	ID93+ GLA-SE)	Placebo	I	2	Adults	(42)
<b>Nell et al.,</b>	2014	SouthAfrica	RUTI	Placebo	II	2	Adults s	(35)
<b>Lutwama et al.,</b>	2014	Uganda	BCG	Delayed	-	1	Infants	(43)
<b>Idoko et al.,</b>	2014	Gambia	M72/AS01	Meningi tis vaccine	II	2	Infants	(32)
<b>Nemes et al.,</b>	2018	SouthAfrica	H4: IC 31& rBCG	Placebo	II	2	Adolescents	(44)
<b>Suliman et al.,</b>	2016	South Africa	BCG	Unvaccin ated	I	1	Adults	(45)
<b>Loxton et al.,</b>	2017	SouthAfrica	VPM1002	BCG	II	1	Infants	(37)
<b>Tameris et al,</b>	2013	SouthAfrica	MVA85A	Placebo	Iib	1	Infants	(46)
<b>Bekker et al.,</b>	2020	SouthAfrica	H4: IC 31, H56: I C31 &  BCG	Placebo	1b	2	Adolescents	(31)



<b>Odutola et al.,</b>	2012	Gambia	MVA85A	EPI	I	1	Infants	(25)
<b>Geldenhuis et al.,</b>	2015	SouthAfrica	BCG	-	I & II	1	Infants and adults	(47)
<b>Hesseling et al.,</b>	2015	SouthAfrica	BCG	-	II	1	Infants	(36)
<b>Kagina et al.,</b>	2014	SouthAfrica	AERAS-402	Placebo	I	2	Infants	(29)
<b>Hatherill et al.,</b>	2014	SouthAfrica	BCG	-	I	1	Adults	(48)
<b>Malaria</b>								
<b>Bell et al.,</b>	2022	Ghana, Malawi, and Gabon	RTS, S/AS01/AS01	Placebo	III	3	Children	(10)
<b>Agnandji et al.,</b>	2014	7 Sub Saharan countries	RTS, S/AS01/AS01E	Meningococcol or rabies	III	3	Infants & children	(49)
<b>Kimani et al.,</b>	2014	Kenya and Gambia	Chad63 &MV A ME-TRAP	Placebo	Ib	2	Adults	(13)
<b>Partnership</b>	2012	7 Sub Saharan countries	RTS, S/AS01 & EPI	Meningococcol vaccine	III	3	Infants	(17)
<b>Dassah et al.,</b>	2021	Ghana, Uganda, Burkina Faso, and Gabon	GMZ2	Rabies	Iib	3	Children	(15)

<b>Otieno et al.,</b>	2020	7 Sub-Saharan countries	RTS, S/AS01/AS01	Meningococcal or rabies vaccine	III	3	Infants and children	(50)
<b>Bejon et al.,</b>	2013	7 Sub Saharan countries	RTS, S/AS01A	Placebo/comparator vaccine	II	3	NA	(51)
<b>Oneko et al.,</b>	2021	Kenya	PfSPZ	Placebo	I & II	1	Infants	(52)
<b>Bell et al.,</b>	2020	Malawi	RTS, S/AS01/AS01	Meningococcal or rabies	III	4	Infants and children	(53)
<b>Ouédraogo et al.,</b>	2013	BurkinaFaso	Ad35.CS.01	Placebo	Ib	3	Adults	(12)
<b>Dejon-Agobe et al.,</b>	2019	Gabon	GMZ2	Rabies vaccine	NA	3	Adults	(16)
<b>Dobaño et al.,</b>	2019	Tanzania, Burkina Faso, and Ghana	RTS, S/AS01/AS01E	Comparator vaccine	III	3	Infants and children	(54)
<b>Mendoza et al.,</b>	2019	7 Sub Saharan Africa	RTS, S/AS01	Menogococcal or rabies	III	4	Infants and children	(55)
<b>Datoo et al.,</b>	2021	Burkina Faso	R21/MM	Rabies vaccine	Iib	3	Children	(56)
<b>Berry et al.,</b>	2019	Mali	FMP2.1/AS02A	Rabies vaccine	II	3	Children	(57)

<b>Sirima et al.,</b>	2017	Burkina Faso	(PfAMA1-DiCo)-GLA SE	Placebo	Ia/Ib	3	Adults	(14)
<b>Moncunill et al.,</b>	2017	Africa	RTS, S/AS01E	Rabies vaccine	III	3	Children	(18)
<b>Han et al.,</b>	2017	Malawi	RTS, S/AS01	Meningococcal & rabies vaccines	III	3-4	Infants and children	(58)
<b>Sissoko et al.,</b>	2017	Mali	PfSPZ	Placebo	I	5	Adults	(22)
<b>Mensah et al.,</b>	2016	Senegal	ChAd 63 & MVA ME-TRAP	Rabies vaccine	II	2	Male adults	(59)
<b>RTS, partnership</b>	2015	7 Sub Saharan countries	RTS, S/AS01/AS01	Comparator vaccine	III	3	Infants and children	(20)
<b>Thera et al.,</b>	2016	Mali	PfAMA1-FVO	Tetanus vaccine	I	3	18-55 men and women	(60)
<b>Ubillos et al.,</b>	2018	Ghana and Mozambique	RTS, S/AS01E	NA	III	3	Infants and children	(61)
<b>Neafsey et al.,</b>	2015	7 Sub-Saharan Africa	RTS, S/AS01	Meningococcal vaccine	III	3	Infants and children	(62)
<b>Gyaase et al.,</b>	2021	Ghana	RTS, S/AS01	Meningococcal vaccine	III	3	Children	(63)
<b>Jongo et al.,</b>	2018	Tanzania	PfSPZ	Placebo	I	5	Men adults	(21)

<b>Chandramahon et al.,</b>	2021	Burkina Faso	RTS, S/AS01 <sub>E</sub>	NA	III	3	Children	(64)
<b>Shekalaghe et al.,</b>	2014	Tanzania	PfSPZ	Placebo	I	2	Adult males	(23)

120

\*7 Sub Saharan countries means: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania.

121

\*TST means Tubercle skin test.

122

123

124


125

126

127

## 128 3.2 Quality assessment

129 The overall quality of all 50 eligible studies was good. 47 (94%) studies received “low risk” overall  
130 status for causing bias, 3 (6%) studies received “some concerns” status (13,18,48), and there were  
131 no articles with “high risk” overall status (**Figure 2**).



132

133 **Figure 2.** Robvis risk assessment summary for all randomised controlled trials in this review.

## 134 3.3 Immunogenicity

135 Immunogenicity varied in magnitude, duration, and type for most malaria and TB vaccine candidates.  
136 Most malaria vaccine candidates had seven times the immunogenicity of humoral immune cells  
137 compared to CD4+ and CD8+ cells, which appeared two times (7.14%). Conversely, TB vaccine  
138 candidates were more immunogenic to CD4+ T cells (72.7%) than CD8+ T cells (45.50%). Most TB  
139 vaccine candidates induce CD4+ and CD8+ cells only (24,29,35,37,43,45,47), followed by CD4+,  
140 CD8+ cells and antibodies only (28,30,31,41) and CD4+ cells and antibodies only (32,42).  
141 Additionally, very few candidates induce only CD4+ cells (11,25,40), and there are no vaccine  
142 candidates that induce CD8+ cells only. These findings demonstrate the immunogenic diversity of  
143 malaria and TB vaccine candidates, emphasising the need for tailored vaccine design and evaluation.

## 144 3.4 Efficacy

145 This review revealed that out of 28 malaria-related studies, only the R21/MM vaccine candidate  
146 (3.8%) had the highest vaccine efficacy (VE) of 77% (56), followed by RTS, S/AS0, 50.3% VE (62),

147 46% VE (49), 45% VE (51), 28% VE (20), 27% VE (49), 12% VE (52), and 18% VE (20), as well  
148 as 8% VE (59) in adults. Other malaria-related studies reported vaccine efficacy qualitatively  
149 (22,63,64). On the other hand, the M72/AS01E TB vaccine candidate showed the highest vaccine  
150 efficacy, 54.0% VE (33), followed by 49.7% VE (39), 45.4% VE, and 30.5% VE (44). In some cases,  
151 MVA85A vaccine candidates have shown insignificant efficacy (24,27). Certain candidates show  
152 promise as disease-fighting tools due to their efficacy. However, insignificant efficacy in some cases  
153 highlights the need for continued research and development to improve malaria and TB vaccines.

### 154 **3.5 Safety**

155 This review revealed that both malaria and TB vaccine candidates had no safety issues that resulted  
156 in the termination of the studies. The common localized adverse effects (AEs) of the malaria vaccine  
157 candidates included injection site swelling (9, 32.14%) and pain (8, 28.6%), whereas the systemic  
158 AEs included headache (12, 42.9%), myalgia, fever, and nausea (8, 28.6%). The severe adverse  
159 effects (SAEs) included malaria (8, 28.6%), meningitis, and febrile convulsion (7; 25%). In contrast,  
160 the common AEs associated with TB vaccine candidates were injection site pain (5, 22.7%) and  
161 systemic abdominal pain (11, 50.0%). The SAEs were gastroenteritis (3, 13.6%). This study found  
162 that vaccine candidates for malaria and TB may cause some side effects, but the risks are generally  
163 tolerable. No studies were stopped due to safety concerns.

## 164 **4. Discussion**

165 The systematic review of 50 studies highlights immunogenicity and efficacy as major challenges in  
166 sub-Saharan African malaria and TB vaccine clinical trials. Safety was not a challenge. However, this  
167 factor should not be ignored in new vaccine development against these diseases since factors such as  
168 dose (23,34,52), vaccine type (44), age group (55), and health status (28) have some impact on safety.  
169 It is critical to evaluate the factors that contribute to variations in immunogenicity and efficacy during  
170 the development of vaccines against malaria and TB, especially in clinical trial settings. Complexities  
171 arise because of factors such as population attributes, vaccine strategy, and pathogen genetic diversity,  
172 all of which influence the immune responses of vaccine candidates. Thus, given the complexity of the

173 factors, it appears that no general conclusion can be drawn regarding the variation.

174 Lack of generalizability, which considered as limitation of evidence in this review, necessitates that  
175 each factor be examined individually. We discovered that population characteristics play the most  
176 important role in variation of immunogenicity and efficacy during malaria and TB vaccine clinical  
177 trials. There is a correlation between age group and vaccine candidate protection. For example, non-  
178 cytophilic antibodies increase the risk of malaria infection while also reducing the immunogenicity  
179 and efficacy of RTS and S/AS01E (61). These antibodies may also explain why malaria is more  
180 common in older people (65). However, the complexity arises when the effects of these antibodies  
181 were found to be more immunogenic in malaria-naïve adults than in semi-immune adults (13). This  
182 finding suggests that infection exposure also contributes to the immunogenicity and efficacy  
183 variations. This was supported by findings that high malaria transmission intensity reduced the  
184 efficacy of RTS, S/AS01 efficacy (10,51). Ideally, older age groups might have more non-cytophilic  
185 antibodies than younger age groups due to the longer exposure time. Immunogenicity and efficacy  
186 improved more in older vaccinees than young ones (15,20,49,58). Furthermore, factors such as lower  
187 socioeconomic status (SES) (63), forest ecological context (53), and season (64) in the respective  
188 region were associated with low efficacy. This contributes to the variations in immunogenicity and  
189 efficacy that are caused by population characteristics.

190 The vaccine strategy significantly influences the immunogenicity and effectiveness of potential  
191 vaccines. This review observes the impact of BCG vaccination on infants at various time points and  
192 found mixed results of TB protection. Vaccination at birth results in more distinct cellular immune  
193 responses than vaccination at 6 weeks (43) or vaccination at 14 weeks (36). In contrast, there was no  
194 significant difference in the prevalence of BCG vaccination at birth or at 8 weeks after delivery.  
195 However, there is a subsequent shift in this response, as infants who were delayed in their attempts to  
196 receive the vaccine demonstrate increased cellular immune responses. These changes could  
197 potentially be attributed to HIV exposure at birth, a period when the immune system lacks the

198 capability to combat the viruses (40). Thus, vaccination timepoints affect vaccine candidate immune  
199 response.

200 This review revealed that the inferior performance of the vaccine candidates was associated with either  
201 poor immunogenicity or a narrow range of immune response inductions. For example, a vaccine study  
202 in which H56:IC31, H4:IC31, and BCG were used induced high antigen specific CD4+ and IgG  
203 expression. However, the number of CD8+ cells induced was very low (31). Boosting with BCG  
204 enhanced only anti-BCG CD4+ but not anti-H4 or anti-H56 IgG antibodies. Similarly, the BCG  
205 booster of MVA85A failed to enhance anti-Ag85A immune responses (44). The induction of a few  
206 immune responses affects the treatment efficacy. Anti-CSP and anti-HB-specific IgG as well as IgM  
207 antibodies defined the efficacy of the RTS and S/AS01 vaccine candidates (61). Despite being  
208 different from one endemic region to another, the efficacy of these agents decreased once the anti-HB  
209 antibodies were not induced (17). Additionally, the lack of PfSPZ vaccine candidate efficacy at 6  
210 months postimmunization was associated with the lack of induction of cellular T immune responses  
211 (52). This showed that multiple immune responses must work together for robust protection. This  
212 factor relates to the vaccine strategy to improve malaria and TB vaccine candidates' immunogenicity  
213 and efficacy in clinical trials.

214 Pathogen genetic diversity affects vaccine immunogenicity and efficacy in clinical trials. Allelic  
215 mismatches between vaccine antigens and natural plasmodium species affect immunogenicity and  
216 efficacy (62). In addition, there were more than 90% mismatches in Sub-Saharan Africa. This might  
217 be another major reason for the diminishing protection efficacy (12,50,58). However, this review  
218 revealed that boosting with additional doses (53,56) and the use of a strong adjuvant (51) might  
219 prevent waning protection. However, continuous boosting might not be useful for low- or middle-  
220 income countries (LMICs), such as Sub-Saharan Africa. Furthermore, adjuvant effects, such as RTS,  
221 S/AS01 and RTS, S/AS02A (51), GMZ2/alum (15), and GMZ2/Alhydrogel/liposomes (16), and  
222 AMA1-DiCo GLA-SE and AMA1-DiCo Alhydrogel (14), have been reported in comparative studies.



223 However, these similar differences were not observed during the GMZ2 Alhydorgel and GMZ2  
224 CFA01 studies (16). Despite this, pre-evaluation of adjuvants for conjugation is crucial. Other vaccine  
225 candidates lacked correlation protection. For example, the FMP2.1/AS02A (57), GMZ2 (15,16),  
226 PfSPZ (21), and MVA-vectored TB candidates were immunogenic but not protective (24,27). This  
227 observation was like that of the Nouatin *et al.* study in Gabon (66). The lack of specificity may have  
228 played a role in these observations.

229 Most of the studies included in this review induced all immune responses (CD4+, CD8+, IgG, IgA,  
230 and IgM). Most CSP-based malaria vaccine candidates induce a greater quantity of anti-NANP  
231 antibodies than anti-C-terminal antibodies (54,56). This might be because the NANP region is  
232 conserved, while the C-terminus is polymorphic (67). The authors added that removing the antigen  
233 parts responsible for the induction of non-neutralizing antibodies might reduce this challenge.  
234 However, the profile of antibodies and CD8+ cells induced by Ad.35.CS.01 was based on the CSP  
235 and Ad35 antigens (12). In HIV-infected vaccinees, the reduction in immune responses was dose  
236 dependent (24,28,29). In some cases, the dose had no effect on immunogenicity (42). Other vaccine  
237 candidates, such as AERAS-402 in infants (41) and MTBVAC in adults and neonates (11), induce  
238 low immune responses at all vaccine dose levels. However, the highest MTBVAC dose was superior  
239 to the equivalent BCG dose. The three H56:IC31 doses were found to be highly immunogenic (68).  
240 In contrast, the highest dose of the RUTI vaccine candidate lost its immunogenicity capability (35).  
241 Furthermore, PfSPZ vaccination in infants induces significant humoral and insignificant cellular  
242 responses (52).

243 This review revealed that M72/AS01E was the most protective TB vaccine candidate (33). However,  
244 another study reported that M72/AS01E had decreased vaccine efficacy with no worsening tendency  
245 (39). These differences were associated with vaccine nature, vaccination strategies, genetic  
246 differences, and health status. The differences in nature of the vaccines used were as follows: BCG  
247 and H4:IC31 (44,69) and H56:IC31, H4:IC31, and BCG (31). Additionally, the immune responses

248 induced during comparative RTS and S/AS01 vaccination between HIV and non-HIV vaccinees were  
249 greater in healthy individuals than in HIV vaccinees (50). These findings are consistent with a  
250 previous study in which HIV vaccinees were shown to reduce immune responses (19). The reduced  
251 immune responses in HIV-infected participants might be due to the ability of HIV to cause immune  
252 response dysfunction. Concomitant vaccination with antiretroviral drugs (ARVs) might reduce the  
253 impacts of these viruses [19].

254 Unfortunately, this review revealed that none of the studies employed mucosal delivery routes. The  
255 mucosal route enhances the speed and efficiency of both localized and systemic humoral and cellular  
256 immune responses, as well as innate and adaptive immune responses. The mucosal MVA85A  
257 immunization in the United Kingdom induced strong immunogenicity, which has not been observed  
258 in South Africa through traditional routes (70). Even though the natural route to malaria infection does  
259 not involve mucosal surfaces, mucosal immunization with malaria-inducing antibodies protects mice  
260 (71). In addition to the immunological point of view, mucosal routes may be more economical than  
261 parenteral routes because they do not require trained personnel and hence are appropriate in resource-  
262 limited sub-Saharan Africa.

263 The review acknowledges the absence of comparison groups and inconsistencies in observations  
264 across studies as limitations of the review processes. Furthermore, comprehensive interpretation of  
265 the findings is complicated by divergences in vaccine administration timing, dosage, and the existence  
266 of confounding variables such as HIV exposure. The ineffectiveness of specific vaccine candidates  
267 can be attributed to their inadequate immunogenicity, which means they elicit a restricted spectrum  
268 of immune responses. This underscores the criticality of refining the process of vaccine development  
269 and assessment. The review emphasises the importance of comprehensive immune responses, which  
270 comprise humoral and cellular components, to provide strong protection against malaria and TB.  
271 Further investigation is warranted to tackle the identified obstacles, including but not limited to  
272 optimising dosing regimens, enhancing the immunogenicity of vaccines that is specific to certain

273 endemic region, and investigating alternative delivery routes such as mucosal administration to  
274 enhance vaccine efficacy, particularly in settings with limited resources like sub-Saharan Africa.

## 275 **5. Conclusion**

276 This review revealed that immunogenicity and efficacy are the major challenges for both malaria and  
277 TB vaccine candidates. The challenges were orchestrated by population characteristics, vaccination  
278 strategies, and pathogen genetic diversity. This review suggested that the continued neglect of these  
279 factors could lengthen the journey toward robust vaccines, that mucosal routes may improve vaccine  
280 candidate performance, and that the development of endemic region-based vaccines is worthwhile.

## 281 **6. Conflict of interest**

282 The authors declare that there are no financial and non-financial conflicts of interests.

## 283 **7. Funding**

284 This review was funded by the Strategic Research Fund (SRF), Ministry of Science, Technology,  
285 and Innovation (MOSTI), Malaysia (Grant number: 305.PPSK.614503). The funder did not  
286 participate at any stage of this study: study design, data analysis and interpretation, report writing,  
287 or submission decision.

## 288 **8. Ethical approval and consent to participate**

289 Note applicable.

## 290 **9. Availability of data and material**

291 All data and materials are available in this manuscript.

## 292 **10. Author contribution**

293 MH conceptualised and designed the study, collected, and interpreted data, and drafted the work. NA  
294 contributed to study conception, design, collection, interpretation, and work drafting. AS contributed  
295 to the data collection, interpretation, and drafting of the work. Furthermore, RS contributed to the

296 conceptualization of the study, data collection, and interpretation. All authors revised and approved  
297 the final version. Also, the authors agreed to be accountable for the contribution made and the  
298 resolution of any questions that would arise about data accuracy or integrity.

## 299 **11. Acknowledgement**

300 We would like to express our gratitude to the Malaysian Ministry of Science, Technology, and  
301 Innovation (MOSTI) for funding this study.

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

## 322 **13. References**

- 323 <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. The top 10 causes of  
324 death.
- 325 Vinicius de Araújo R, Silva Santos S, Missfeldt Sanches L, Giarolla J, El Seoud O, Igne Ferreira E.  
326 Malaria, and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and  
327 advances in the search for new drugs. Mem Inst Oswaldo Cruz. 2020.
- 328 Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Vol. 391, The Lancet. Lancet Publishing Group;  
329 2018. p. 1608–21.
- 330 WHO. World malaria report 2022 [Internet]. 2022. Available from:  
331 <https://www.who.int/teams/global-malaria-programme>
- 332 Rossati A, Bargiacchi O, Kroumova V, Zaramella M, Caputo A, Garavelli PL. Climate, environment,  
333 and transmission of malaria. Infezioni in Medicina. 2016;24(2):93–104.
- 334 CDC. CDC - Malaria - Malaria Worldwide - Impact of Malaria. 2021.
- 335 WHO. Global Tuberculosis report 2022 [Internet]. 2022. Available from:  
336 <http://apps.who.int/bookorders>.
- 337 WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. 2018.
- 338 WHO. World malaria report 2016. 2016. 148 p.
- 339 Bell GJ, Goel V, Essone P, Dosoo D, Adu B, Mensah BA, et al. Malaria Transmission Intensity Likely  
340 Modifies RTS, S/AS01 Efficacy Due to a Rebound Effect in Ghana, Malawi, and Gabon. Journal of  
341 Infectious Diseases. 2022;226(9):1646–56.
- 342 Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, et al. Live-attenuated  
343 *Mycobacterium tuberculosis* vaccine MTBVAC versus BCG in adults and neonates: a randomised  
344 controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019 Oct;7(9):757–70.
- 345 Ouédraogo A, Tiono AB, Kargougou D, Yaro JB, Ouédraogo E, Kaboré Y, et al. A phase 1b  
346 randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity  
347 and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe

- 348 healthy adults 18 to 45 years of age. PLoS One. 2013 Oct;8(11).
- ~~349~~ Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, et al. Translating the Immunogenicity of  
350 Prime-boost Immunization with ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-  
351 endemic Populations. Molecular Therapy. 2014;22(11):1992–2003.
- ~~352~~ Sirima SB, Durier C, Kara L, Houard S, Gansane A, Loulergue P, et al. Safety and immunogenicity  
353 of a recombinant *Plasmodium falciparum* AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or  
354 Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre  
355 trial. Vaccine. 2017 Oct;35(45):6218–27.
- ~~356~~ Dassah S, Adu B, Sirima SB, Mordmüller B, Ngoa UA, Atuguba F, et al. Extended follow-up of  
357 children in a phase2b trial of the GMZ2 malaria vaccine. Vaccine. 2021 Oct;39(31):4314–9.
- ~~358~~ Dejon-Agobe JC, Ateba-Ngoa U, Lalremruata A, Homoet A, Engelhorn J, Nouatin OP, et al.  
359 Controlled Human Malaria Infection of Healthy Adults with Lifelong Malaria Exposure to Assess  
360 Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.  
361 Clinical Infectious Diseases. 2019 Oct;69(8):1377–84.
- ~~362~~ Partnership. A Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in African Infants. New England  
363 Journal of Medicine. 2012 Oct;367(24):2284–95.
- ~~364~~ Moncunill G, Rosa SC De, Ayestaran A, Nhabomba AJ, Mpina M, Cohen KW, et al. RTS, S/AS01E  
365 Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase  
366 III Trial. Front Immunol. 2017;8.
- ~~367~~ Otieno L, Oneko M, Otieno W, Abuodha J, Owino E, Odero C, et al. Safety and immunogenicity of  
368 RTS, S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a  
369 randomised, double-blind, controlled trial. [www.thelancet.com/infection](http://www.thelancet.com/infection) [Internet]. 2016;16.  
370 Available from: <http://dx.doi.org/10.1016/>
- ~~371~~ RTS SCTP, Tinto H, D’Alessandro U, Sorgho H, Valea I, Tahita MC, et al. Efficacy and safety of  
372 RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final  
373 results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.

- ~~374~~ Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of *Plasmodium falciparum* sporozoite vaccine in Tanzanian adults. *American Journal of Tropical Medicine and Hygiene*. 2018;99(2):338–49.
- ~~375~~ Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against *Plasmodium falciparum* via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. *Lancet Infect Dis*. 2017 Oct;17(5):498–509.
- ~~376~~ Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved *Plasmodium falciparum* sporozoites. *American Journal of Tropical Medicine and Hygiene*. 2014 Oct;91(3):471–80.
- ~~377~~ Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: A randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2015 Oct;3(3):190–200.
- ~~378~~ Odotola AA, Owolabi OA, Owiafe PK, McShane H, Ota MOC. A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. *Vaccine*. 2012 Oct;30(38):5591–4.
- ~~379~~ Nemes E, Hesselning AC, Tameris M, Mauff K, Downing K, Mulenga H, et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed bacille calmette-guerin for infants of human immunodeficiency virus-infected mothers: A phase 2 randomized, controlled trial. *Clinical Infectious Diseases*. 2018 Feb 15;66(4):554–63.
- ~~380~~ Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. *Lancet*. 2013;381(9871):1021–8.
- ~~381~~ Churchyard GJ, Snowden MA, Hokey D, Dheenadhayalan V, McClain JB, Douoguih M, et al. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-

- 400 vaccinated adults with CD4+ T cell counts >350 cells/mm<sup>3</sup>. *Vaccine*. 2015 Oct;33(15):1890–6.
- ~~401~~ Kagina BMN, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, et al. The novel  
402 tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and  
403 induces dose-dependent CD4 and CD8T cell responses. *Vaccine*. 2014 Oct;32(45):5908–17.
- ~~404~~ Walsh DS, Owira V, Polhemus M, Otieno L, Andagalu B, Ogutu B, et al. Adenovirus type 35-vectored  
405 tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated,  
406 QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis. *Vaccine*. 2016  
407 Oct;34(21):2430–6.
- ~~408~~ Bekker LG, Dintwe O, Fiore-Gartland A, Middelkoop K, Hutter J, Williams A, et al. A phase Ib  
409 randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31,  
410 and BCG revaccination in *Mycobacterium tuberculosis*-uninfected adolescents in Cape Town, South  
411 Africa. *EClinicalMedicine*. 2020;21.
- ~~412~~ Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A, et al. Safety and  
413 immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in  
414 Gambian infants: An open label randomized controlled trial. *Tuberculosis*. 2014 Oct;94(6):564–78.
- ~~415~~ Meeren O Van Der, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Brakel E Van, et al. Phase  
416 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. *New England Journal of*  
417 *Medicine*. 2018 Oct;379(17):1621–34.
- ~~418~~ Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, et al. Safety and  
419 immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. *Vaccine*.  
420 2015 Oct;33(32):4025–34.
- ~~421~~ Nell AS, D’Lom E, Bouic P, Sabaté M, Bosser R, Picas J, et al. Safety, tolerability, and  
422 immunogenicity of the novel antituberculous vaccine RUTI: Randomized, placebo-controlled phase  
423 II clinical trial in patients with latent tuberculosis infection. *PLoS One*. 2014 Oct;9(2).
- ~~424~~ Hesseling AC, Jaspan HB, Black GF, Nene N, Walzl G. Immunogenicity of BCG in HIV-exposed  
425 and non-exposed infants following routine birth or delayed vaccination. *International Journal of*



- 426 Tuberculosis and Lung Disease. 2015 Oct;19(4):454–62.
- ~~427~~ 427. Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B, et al. Safety and immunogenicity  
428 of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants  
429 in South Africa. *Clinical and Vaccine Immunology*. 2017 Oct;24(2).
- ~~430~~ 430. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance  
431 for reporting systematic reviews: development of the PRISMA 2020 statement What is new? *J Clin*  
432 *Epidemiol* [Internet]. 2021; 134:103–12. Available from:  
433 <https://doi.org/10.1016/j.jclinepi.2021.02.003>
- ~~434~~ 434. Tait DR, Hatherill M, Meeren O Van Der, Ginsberg AM, Brakel E Van, Salaun B, et al. Final Analysis  
435 of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. *New England Journal of Medicine*. 2019  
436 Oct;381(25):2429–39.
- ~~437~~ 437. Tchakoute CT, Hesselning AC, Kidzeru EB, Gamiieldien H, Passmore JAS, Jones CE, et al. Delaying  
438 BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed  
439 infants. *Journal of Infectious Diseases*. 2015 Oct;211(3):338–46.
- ~~440~~ 440. Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, et al. A double-blind, randomised,  
441 placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-  
442 vectored fusion protein, in healthy, BCG-vaccinated infants. *Vaccine*. 2015 Oct;33(25):2944–54.
- ~~443~~ 443. Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, et al. Safety and  
444 immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults  
445 in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. *Lancet Respir Med*.  
446 2018 Oct;6(4):287–98.
- ~~447~~ 447. Lutwama F, Kagina BM, Wajja A, Waiswa F, Mansoor N, Kirimunda S, et al. Distinct T-Cell  
448 Responses When BCG Vaccination Is Delayed from Birth to 6 Weeks of Age in Ugandan Infants.  
449 *Journal of Infectious Diseases*. 2014;209(6):887–97.
- ~~450~~ 450. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M.  
451 tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. *New England Journal of*

- 452 Medicine. 2018 Oct;379(2):138–49.
- ~~453~~ Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, et al. Bacillus Calmette–  
454 Guérin (BCG) Revaccination of Adults with Latent *Mycobacterium tuberculosis* Infection Induces  
455 Long-Lived BCG-Reactive NK Cell Responses. The Journal of Immunology. 2016 Oct;197(4):1100–  
456 10.
- ~~457~~ Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy  
458 of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised,  
459 placebo-controlled phase 2b trial. The Lancet. 2013;381(9871):1021–8.
- ~~460~~ Geldenhuys HD, Mearns H, Foster J, Saxon E, Kagina B, Saganic L, et al. A randomized clinical trial  
461 in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette–  
462 Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique  
463 with needle and syringe. Vaccine. 2015 Oct;33(37):4719–26.
- ~~464~~ Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, et al. Safety and  
465 reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine.  
466 2014 Oct;32(31):3982–8.
- ~~467~~ Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Kabwende AL, Adegnika AA, et al. Efficacy and  
468 Safety of the RTS, S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3  
469 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLoS Med.  
470 2014;11(7).
- ~~471~~ Otieno L, Mendoza YG, Adjei S, Agbenyega T, Agnandji ST, Aide P, et al. Safety and  
472 immunogenicity of the RTS, S/AS01 malaria vaccine in infants and children identified as HIV-  
473 infected during a randomized trial in sub-Saharan Africa. Vaccine. 2020 Oct;38(4):897–906.
- ~~474~~ Bejon P, White MT, Olotu A, Bojang K, Lusingu JPA, Salim N, et al. Efficacy of RTS, S malaria  
475 vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infectious Diseases.  
476 2013;13(4):319–27.
- ~~477~~ Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Natasha KC, et al. Safety,

478 immunogenicity, and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a  
479 double-blind, randomized, placebo-controlled phase 2 trial. *Nat Med.* 2021;27(9):1636-+.

~~480~~ Bell GJ, Loop MS, Mvalo T, Juliano JJ, Mofolo I, Kamthunzi P, et al. Environmental modifiers of  
481 RTS, S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. *BMC Public Health.* 2020;20(1).

~~482~~ Dobaño C, Sanz H, Sorgho H, Dosoo D, Mpina M, Ubillos I, et al. Concentration and avidity of  
483 antibodies to different circumsporozoite epitopes correlate with RTS, S/AS01E malaria vaccine  
484 efficacy. *Nat Commun.* 2019 Oct;10(1).

~~485~~ Mendoza Y, Garric E, Leach A, Lievens M, Ofori-Anyinam O, Pirçon JY, et al. Safety profile of the  
486 RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized  
487 controlled trial in sub-Saharan Africa. *Hum Vaccin Immunother.* 2019 Oct;15(10):2386–98.

~~488~~ Dattoo MS, Natama MH, Some A, Traore O, Rouamba T, Bellamy D, et al. Efficacy of a low-dose  
489 candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in  
490 Burkina Faso: a randomised controlled trial. *Lancet.* 2021;397(10287):1809–18.

~~491~~ Berry AA, Gottlieb ER, Kouriba B, Diarra I, Thera MA, Dutta S, et al. Immunoglobulin G subclass  
492 and antibody avidity responses in Malian children immunized with *Plasmodium falciparum* apical  
493 membrane antigen 1 vaccine candidate FMP2.1/AS02(A). *Malar J.* 2019;18.

~~494~~ Han L, Hudgens MG, Emch ME, Juliano JJ, Keeler C, Martinson F, et al. RTS, S/AS01 Malaria  
495 Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized  
496 Controlled Trial in Malawi. *Sci Rep.* 2017 Oct;7(1).

~~497~~ Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, et al. Safety,  
498 immunogenicity, and efficacy of prime-Boost vaccination with Chad63 and MVA encoding me-  
499 TRAP against *Plasmodium falciparum* infection in adults in Senegal. *PLoS One.* 2016 Oct;11(12).

~~500~~ Thera MA, Coulibaly D, Kone AK, Guindo AB, Traore K, Sall AH, et al. Phase 1 randomized  
501 controlled trial to evaluate the safety and immunogenicity of recombinant *Pichia pastoris*-expressed  
502 *Plasmodium falciparum* apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian  
503 adults in Bandiagara. *Malar J.* 2016 Oct;15(1).

- 504 Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jiménez A, et al. Baseline exposure,  
505 antibody subclass, and hepatitis B response differentially affect malaria protective immunity  
506 following RTS, S/AS01E vaccination in African children. *BMC Med.* 2018 Oct;16(1).
- 507 Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic Diversity and  
508 Protective Efficacy of the RTS, S/AS01 Malaria Vaccine. *New England Journal of Medicine.* 2015  
509 Oct;373(21):2025–37.
- 510 Gyaase S, Asante KP, Adeniji E, Boahen O, Cairns M, Owusu-Agyei S. Potential effect modification  
511 of RTS, S/AS01 malaria vaccine efficacy by household socio-economic status. *BMC Public Health.*  
512 2021;21(1).
- 513 Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, et al. Seasonal Malaria  
514 Vaccination with or without Seasonal Malaria Chemoprevention. *New England Journal of Medicine.*  
515 2021;385(11):1005–17.
- 516 Tinto H, Otieno W, Gesase S, Sorgho H, Otieno L, Liheluka E, et al. Long-term incidence of severe  
517 malaria following RTS, S/AS01 vaccination in children and infants in Africa: an open-label 3-year  
518 extension study of a phase 3 randomised controlled trial. *Lancet Infect Dis.* 2019 Aug 1;19(8):821–  
519 32.
- 520 Nouatin O, Ibáñez J, Fendel R, Ngoa UA, Lorenz FR, Dejon-Agobé JC, et al. Cellular and antibody  
521 response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial.  
522 *Malar J.* 2022 Dec 1;21(1).
- 523 Langowski MD, Khan FA, Savransky S, Brown DR, Balasubramaniam A, Harrison WB, et al.  
524 Restricted valency (NPNA)<sub>n</sub> repeats and junctional epitope-based circumsporozoite protein vaccines  
525 against *Plasmodium falciparum*. *NPJ Vaccines.* 2022 Dec 1;7(1).
- 526 Suliman S, Luabeya AKK, Geldenhuys H, Tameris M, Hoff ST, Shi Z, et al. Dose optimization of  
527 H56:IC31 vaccine for tuberculosis-endemic populations a double-blind, placebo-controlled, dose-  
528 selection trial. *Am J Respir Crit Care Med.* 2019 Jan 15;199(2):220–31.
- 529 Geldenhuys H, Mearns H, Miles DJC, Tameris M, Hokey D, Shi Z, et al. The tuberculosis vaccine

530 H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults:  
531 A randomized controlled trial. *Vaccine*. 2015 Jul 9;33(30):3592–9.

~~532~~ Riste M, Marshall JL, Satti I, Harris SA, Wilkie M, Ramon RL, et al. Phase i trial evaluating the safety  
533 and immunogenicity of candidate tb vaccine mva85a, delivered by aerosol to healthy Mtb-infected  
534 adults. *Vaccines (Basel)*. 2021;9(4).

~~535~~ Saveria T, Parthiban C, Seilie AM, Brady C, Martinez A, Manocha R, et al. Needle-free, spirulina-  
536 produced *Plasmodium falciparum* circumsporozoite vaccination provides sterile protection against  
537 pre-erythrocytic malaria in mice. *NPJ Vaccines*. 2022 Dec 1;7(1).

538